Investigating the effectiveness of esketamine in reducing depression for breast cancer patients after surgery
- Conditions
- Breast cancer with postoperative depressive symptomsCancer
- Registration Number
- ISRCTN12578022
- Lead Sponsor
- The First Affiliated Hospital of University of South China
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 108
1. HAMD-17 score between 8 and 24 (mild to severe depressive symptoms)
2. Age range between 18 and 65 years
3. American Society of Anesthesiologists (ASA) physical status classification of I-II
4. Confirmed diagnosis of breast cancer and planned unilateral radical mastectomy for breast cancer
1. HAMD-17 score of greater than 24 or less than 7
2. Other psychiatric disorders (e.g., schizophrenia and bipolar disorder)
3. History of psychiatric disorders prior to the study
4. Patients who have used psychotropic medications or have other serious systemic illnesses (including serious heart, kidney, or liver disease)
5. Contraindication or allergy to the use of esketamine
6. Planned surgery other than radical mastectomy alone (e.g., reconstruction)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hamilton Depression Scale (HAMD-17) scores at baseline and 6 months postoperatively
- Secondary Outcome Measures
Name Time Method 1. HAMD-17 score changes at baseline (pre-surgery) and 6 months post-surgery<br>2. Patient demographic data (age, weight, height, pathology type)measured by review of patient medical records at the time of enrollment<br>